Next 10 |
2024-03-21 18:57:54 ET Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my p...
2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...
2024-03-19 19:08:05 ET Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Conference Call March 19, 2024, 04:30 PM ET Company Participants Tim McCarthy - IR, Advisors Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Basma Radwan...
2024-03-19 16:22:18 ET More on Relmada Therapeutics Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Ther...
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
2024-03-18 17:35:40 ET More on Relmada Therapeutics Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Ther...
2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 PR Newswire CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biote...
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference PR Newswire CORAL GABLES, Fla. , March 5, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central...
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 PR Newswire CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biote...